Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets

Victor C. Huber, Jonathan Mccullers

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Patients undergoing chemotherapy for cancer are highly susceptible to influenza virus infection. Prevention of influenza virus infection is complicated in the immunocompromised host because of suboptimal responses to the trivalent inactivated influenza vaccine (TIV). A new, live attenuated influenza vaccine (LAIV; FluMist) may offer a more effective alternative to TIV, but the safety of this LAIV in immunocompromised patients must first be established. In the present study, FluMist was administered to ferrets immunocompromised by treatment with dexamethasone and cytarabine. Ferrets exhibited no signs or symptoms attributable to FluMist, and nasal clearance of LAIV strains from immunocompromised ferrets was similar to that from control ferrets. Serum antibody responses against the vaccinating strains were analyzed as a measure of vaccine efficacy. Antibody titers to all 3 vaccine strains in immunocompromised ferrets were similar to those seen in mock-treated control ferrets, as assessed by microneutralization assay. These findings support the potential use of this vaccine in immunocompromised humans.

Original languageEnglish (US)
Pages (from-to)677-684
Number of pages8
JournalJournal of Infectious Diseases
Volume193
Issue number5
DOIs
StatePublished - Mar 1 2006

Fingerprint

Attenuated Vaccines
Ferrets
Influenza Vaccines
Inactivated Vaccines
Vaccines
Immunocompromised Host
Virus Diseases
Orthomyxoviridae
Cytarabine
Nose
Dexamethasone
Signs and Symptoms
Antibody Formation
Safety
Drug Therapy
Antibodies
Serum
Neoplasms

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets. / Huber, Victor C.; Mccullers, Jonathan.

In: Journal of Infectious Diseases, Vol. 193, No. 5, 01.03.2006, p. 677-684.

Research output: Contribution to journalArticle

@article{4897957215764245a0a19cc5c5a3f276,
title = "Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets",
abstract = "Patients undergoing chemotherapy for cancer are highly susceptible to influenza virus infection. Prevention of influenza virus infection is complicated in the immunocompromised host because of suboptimal responses to the trivalent inactivated influenza vaccine (TIV). A new, live attenuated influenza vaccine (LAIV; FluMist) may offer a more effective alternative to TIV, but the safety of this LAIV in immunocompromised patients must first be established. In the present study, FluMist was administered to ferrets immunocompromised by treatment with dexamethasone and cytarabine. Ferrets exhibited no signs or symptoms attributable to FluMist, and nasal clearance of LAIV strains from immunocompromised ferrets was similar to that from control ferrets. Serum antibody responses against the vaccinating strains were analyzed as a measure of vaccine efficacy. Antibody titers to all 3 vaccine strains in immunocompromised ferrets were similar to those seen in mock-treated control ferrets, as assessed by microneutralization assay. These findings support the potential use of this vaccine in immunocompromised humans.",
author = "Huber, {Victor C.} and Jonathan Mccullers",
year = "2006",
month = "3",
day = "1",
doi = "10.1086/500247",
language = "English (US)",
volume = "193",
pages = "677--684",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets

AU - Huber, Victor C.

AU - Mccullers, Jonathan

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Patients undergoing chemotherapy for cancer are highly susceptible to influenza virus infection. Prevention of influenza virus infection is complicated in the immunocompromised host because of suboptimal responses to the trivalent inactivated influenza vaccine (TIV). A new, live attenuated influenza vaccine (LAIV; FluMist) may offer a more effective alternative to TIV, but the safety of this LAIV in immunocompromised patients must first be established. In the present study, FluMist was administered to ferrets immunocompromised by treatment with dexamethasone and cytarabine. Ferrets exhibited no signs or symptoms attributable to FluMist, and nasal clearance of LAIV strains from immunocompromised ferrets was similar to that from control ferrets. Serum antibody responses against the vaccinating strains were analyzed as a measure of vaccine efficacy. Antibody titers to all 3 vaccine strains in immunocompromised ferrets were similar to those seen in mock-treated control ferrets, as assessed by microneutralization assay. These findings support the potential use of this vaccine in immunocompromised humans.

AB - Patients undergoing chemotherapy for cancer are highly susceptible to influenza virus infection. Prevention of influenza virus infection is complicated in the immunocompromised host because of suboptimal responses to the trivalent inactivated influenza vaccine (TIV). A new, live attenuated influenza vaccine (LAIV; FluMist) may offer a more effective alternative to TIV, but the safety of this LAIV in immunocompromised patients must first be established. In the present study, FluMist was administered to ferrets immunocompromised by treatment with dexamethasone and cytarabine. Ferrets exhibited no signs or symptoms attributable to FluMist, and nasal clearance of LAIV strains from immunocompromised ferrets was similar to that from control ferrets. Serum antibody responses against the vaccinating strains were analyzed as a measure of vaccine efficacy. Antibody titers to all 3 vaccine strains in immunocompromised ferrets were similar to those seen in mock-treated control ferrets, as assessed by microneutralization assay. These findings support the potential use of this vaccine in immunocompromised humans.

UR - http://www.scopus.com/inward/record.url?scp=33144487254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144487254&partnerID=8YFLogxK

U2 - 10.1086/500247

DO - 10.1086/500247

M3 - Article

VL - 193

SP - 677

EP - 684

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -